ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Hydroxychloroquine"

  • Abstract Number: 1490 • 2016 ACR/ARHP Annual Meeting

    Metabolic and Cardio-Vascular Benefits of Hydroxychloroquine in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis

    Claire Rempenault1, Thomas Barnetche2, Jacques Morel3, Cédric Lukas4, Cécile Gaujoux-Viala5, Bernard Combe6 and Charlotte Hua7, 1Rheumatology, CHU Lapeyronie, University of Montpellier, France, 2Rheumatology Department, Pellegrin University Hospital, BORDEAUX, France, 3Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France, 4Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, 5Rheumatology Department, University Hospital of Nîmes and EA2415, Montpellier University, Nîmes, France, 6Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, 7Department of Rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France

    Background/Purpose: Cardiovascular disease (CVD) is the leading cause of mortality in rheumatoid arthritis (RA) patients. Hydroxychloroquine (HCQ) has been shown to improve major outcomes like…
  • Abstract Number: 1504 • 2016 ACR/ARHP Annual Meeting

    Fluoroquinolone Resistance in Escherichia coli Urinary Tract Infections Among Patients with Rheumatoid Arthritis: Does Use of Hydroxichloroquine Matter?

    Karen Ferez-Blando1, Hilda Fragoso-Loyo2, Alfredo Ponce de León3, Sergio Ponce de Leon-Rosales4 and Yemil Atisha-Fregoso1, 1Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, 2Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 3Department of Infectology and Microbiology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 4Direccion de Enseñanza, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease that requires chronic immunosuppressive treatment. Urinary tract infections (UTI) are common among patients with RA. It…
  • Abstract Number: 1817 • 2016 ACR/ARHP Annual Meeting

    A Longitudinal Analysis of Change in Lupus Disease Activity Pattern in Hopkins Lupus Cohort Using a Multistate Markov Model Approach

    Wei Fu1 and Michelle Petri2, 1Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 2Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multi-systemic inflammatory disease with extreme variability of its activity over time. We have described three main patterns: long…
  • Abstract Number: 2047 • 2016 ACR/ARHP Annual Meeting

    Impact of in Utero Hydroxychloroquine Exposure on the Risk of Cutaneous Neonatal Lupus Erythematosus

    Julie Barsalou1, Nathalie Costedoat-Chalumeau2, Adey Berhanu3, Cesar Fors-Nieves4, Ummara Shah5, Patrick Brown6, Carl Laskin7, Nathalie Morel8, Kateri Levesque9, Jill P. Buyon10, Earl Silverman6 and Peter M. Izmirly11, 1Pediatric Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, 2Internal Medicine, Cochin University Hospital, Paris, France, 3Rheumatology Fellowship Program, NYU Langone Medical Center/NYU School of Medicine, New York, NY, 4Division of Rheumatology, NYU School of Medicine, New York, NY, 5Medicine, Strong Memorial Hospital, University of Rochester, Rochester, NY, 6University of Toronto, Toronto, ON, Canada, 7Medicine, Rheumatology and Obstetrics and Gynecology, University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, Canada, 8Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, 9Internal Medicine, CHU Ste-Justine, Montréal, QC, Canada, 10Medicine, Tisch Hospital, New York, NY, 11New York University School of Medicine, New York, NY

    Background/Purpose: Histopathologic studies of cutaneous neonatal lupus erythematosus (cNLE) lesions usually show interface dermatitis. Hydroxychloroquine (HCQ) is an effective treatment for interface dermatitis seen in…
  • Abstract Number: 2322 • 2016 ACR/ARHP Annual Meeting

    The Clinical Significance of Curvilinear Bodies on Ultrastructural Examination of Muscle

    Thomas Khoo1, Sophia Otto2, Barbara Koszyka2, Caroline Smith2, Peter Blumbergs3, Sue Lester4 and Vidya Limaye5, 1Medical Student, University of Adelaide, Adelaide, Australia, 2Anatomical Pathology, SA Pathology, Adelaide, Australia, 3Pathology, University of Adelaide, Adelaide, Australia, 4Rheumatology, The Queen Elizabeth Hospital, Adelaide, Australia, 5Rheumatology, Royal Adelaide Hospital, Adelaide, Australia

    Background/Purpose:  The electronic database of muscle biopsies reported in the Anatomical Pathology Laboratory, SA Pathology was searched from 2006 to the present, to identify biopsies…
  • Abstract Number: 2433 • 2016 ACR/ARHP Annual Meeting

    Trends  in Use of Hydroxychloroquine during Pregnancy in SLE Patients from 2001 to 2012

    Bonnie L. Bermas1, Seoyoung Kim2,3, Krista Huybrechts4, Sonia Hernandez-diaz5, Brian T. Bateman6 and Rishi J. Desai7, 1Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 2Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 3Division of Pharmacoepidemiology and Pharmocoeconomics, Brigham and Women's Hospital, Boston, MA, 4Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, 5Harvard School of Public Health, Boston, MA, 6Division of Pharmacoepidemiology and Pharocoeconomics, Brigham and Women's Hospital, Boston, MA, 7PharmacoEpidemiology & PharmacoEconomics, Brigham & Women's Hospital, Boston, MA

    Background/Purpose : Data suggest that hydroxychloroquine (HCQ) use during systemic lupus erythematosus (SLE) pregnancies improves outcomes. In the past decade, single-center studies report that a…
  • Abstract Number: 2453 • 2016 ACR/ARHP Annual Meeting

    The Prevention, Screening, and Treatment of Congenital Heart Block from Neonatal Lupus: A Survey of Provider Practices

    Megan E. B. Clowse1, Amanda M. Eudy2, Bonnie L. Bermas3, Eliza Chakravarty4, Lisa R. Sammaritano5 and Christina D. Chambers6, 1Rheumatology, Duke University School of Medicine, Durham, NC, 2Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 3Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 4Edmond, OK, 5Rheumatology, Hospital for Special Surgery, New York, NY, 6Pediatrics, University of California, San Diego, La Jolla, CA

    Background/Purpose: There are presently no official guidelines about the prevention, screening, and treatment of congenital heart block (CHB) due to maternal Ro antibodies. The objective…
  • Abstract Number: 2456 • 2016 ACR/ARHP Annual Meeting

    Risk Factors for Adverse Pregnancy Outcome in Antiphospholipid Antibodies Carriers: Results from a Multicenter Italian Cohort over 20 Years of Experience

    Maria Grazia Lazzaroni1, Laura Andreoli1, Cecilia B. Chighizola2, Teresa Del Ross3, Maria Gerosa4, Anna Kuzenko3, Maria Gabriella Raimondo4, Andrea Lojacono5, Sonia Zatti5, Francesca Ramazzotto5, Laura Trespidi6, Pier Luigi Meroni7, Vittorio Pengo3, Amelia Ruffatti3 and Angela Tincani1, 1Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, 2Department of Clinical Sciences and Community Health, University of Milan, IRCCS Istituto Auxologico Italiano, Milano, Italy, 3Azienda Ospedaliera of Padova, University of Padova, Padova, Italy, 4University of Milan, Istituto Ortopedico Gaetano Pini, Milano, Italy, 5Obstetrics and Gynecology, Spedali Civili and University of Brescia, Brescia, Italy, 6L.Mangiagalli Obstetric Clinic, IRCSS Cà Granda, Ospedale Maggiore of Milano, Milano, Italy, 7Hospital G.Pini, University of Milano, IRCSS Instute Auxologico Italiano, Milano, Italy

    Risk Factors for Adverse Pregnancy Outcome in Antiphospholipid Antibodies Carriers: Results From a Multicenter Italian Cohort Over 20 Years Of Experience Background/Purpose: Antiphospholipid antibodies (aPL)…
  • Abstract Number: 425 • 2015 ACR/ARHP Annual Meeting

    Impact of in Utero Hydroxychloroquine Exposure on Age of Onset of Cutaneous Neonatal Lupus

    Julie Barsalou1, Nathalie Costedoat-Chalumeau2, Cesar Fors-Nieves3, Ummara Shah4, Patrick Brown5, Carl Laskin6, Nathalie Morel2, Kateri Levesque7, Jill P. Buyon8, Earl Silverman9 and Peter M. Izmirly10, 1Pediatric Rheumatology, CHU Sainte-Justine, Université de Montréal, Montréal, QC, Canada, 2Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, 3Division of Rheumatology, NYU School of Medicine, New York, NY, 4Medicine, Strong Memorial Hospital, University of Rochester, Rochester, NY, 5University of Toronto, Toronto, ON, Canada, 6Medicine, Rheumatology and Obstetrics and Gynecology, University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, Canada, 7Internal Medicine, CHU Ste-Justine, Montréal, QC, Canada, 8NYU School of Medicine, New York, NY, 9Division of Rheumatology, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, 10Rheumatology, NYU School of Medicine, New York, NY

    Background/Purpose: Biopsy specimens of cutaneous neonatal lupus (cNL) lesions usually show interface dermatitis. Hydroxychloroquine (HCQ) is an effective treatment for interface dermatitis seen in connective…
  • Abstract Number: 484 • 2015 ACR/ARHP Annual Meeting

    Race Plays a Role in Influencing the Modest Lipid Lowering Effects of Hydroxychloroquine in Patients with Rheumatoid Arthritis, Independent of Statin Use

    Myriam Guevara1, Bernard NG1 and Nancy Gove2, 1Rheumatology, University of Washington, Seattle, WA, 2Biostatistics, Seattle Children's, Seattle, WA

    Background/Purpose: Despite remarkable improvements in RA treatment, there is evidence indicating that the mortality gap between RA patients and the general population is not closing.…
  • Abstract Number: 2107 • 2015 ACR/ARHP Annual Meeting

    Initiation of Combination Triple Therapy in Real World Clinical Practice Rarely Replicates the Protocols Used in Randomized Controlled Trials.

    Grant W. Cannon1, Chia-Chen Teng2, Ted R. Mikuls3, Jeffrey R. Curtis4, Derek Tang5, Bradley S. Stolshek5 and Brian Sauer6, 1Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, 2HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, 3Veteran Affairs Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, 4University of Alabama at Birmingham, Birmingham, AL, 5Amgen, Inc., Thousand Oaks, CA, 6Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT

    Background/Purpose:   Combination therapy with methotrexate (MTX), sulfasalazine (SUL), and hydroxychloroquine (HCQ) [triple therapy] is an effective treatment for rheumatoid arthritis (RA).   Randomized controlled trials…
  • Abstract Number: 2483 • 2015 ACR/ARHP Annual Meeting

    Adherence to 2011 American Academy of Ophthalmology Guidelines to Perform Objective Screening Tests for Detection of Antimalarial Retinal Toxicity Is Suboptimal

    Sarah Haserodt1, Chris Tonner2, Sara G. Murray3, Gabriela Schmajuk4 and Jinoos Yazdany5, 1Internal Medicine, California Pacific Medical Center, San Francisco, CA, 2Rheumatology, University of California, San Francisco, San Francisco, CA, 3Medicine, University of California, San Francisco, San Francisco, CA, 4Medicine/ Rheumatology, UCSF/ San Francisco VA, San Francisco, CA, 5University of California, San Francisco, San Francisco, CA

    Background/Purpose: American Academy of Ophthalmology (AAO) 2011 guidelines recommend that patients receiving hydroxychloroquine (HCQ) or chloroquine (CQ) undergo regular screening for retinal toxicity with 1…
  • Abstract Number: 2374 • 2014 ACR/ARHP Annual Meeting

    Use of Hydroxychloroquine Associated with Improved Lipid Profile in Rheumatoid Arthritis Patients

    Jose Felix Restrepo1, Inmaculada del Rincon2, Emily Molina3, Daniel Battafarano4 and Agustin Escalante5, 1Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, 2Medicine/Clinical Immunology, UTHSCSA, San Antonio, TX, 3Rheumatology, University of Texas Health Science Center, San Antonio, TX, 4Rheumatology, San Antonio Military Medical Center, JBSA - Ft Sam Houston, TX, 5Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX

    Background/Purpose:   Cardiovascular disease (CVD) is one of the leading causes of morbidity and mortality in rheumatoid arthritis (RA). CVD risk factor reduction, such as reducing…
  • Abstract Number: 1846 • 2014 ACR/ARHP Annual Meeting

    The Association Between Hydroxychloroquine Treatment and Cardiovascular Morbidity Among Rheumatoid Arthritis Patients

    Michael Shapiro1 and Yair Levy2, 1Haim Lebanon 55, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 2Internal Medicine E, Meir Medical Center, Kfar Saba, Israel

    Background/Purpose: Accelerated atherosclerosis and cardiovascular disease are the main causes of mortality in Rheumatoid Arthritis (RA). The anti-malarial drug Hydroxychloroquine (HCQ) has long been used…
  • Abstract Number: 1614 • 2013 ACR/ARHP Annual Meeting

    Hydroxychloroquine Reverse The Elevation Of Interferon-Alfa Initiated By TLR-9 Agonist Which Irresponsive To Glucocorticoid

    Ou Jin1, Xi Zhang1, Lingkai Fang1, Qiuxia Li1, Hongyue Huang1, Zhiming Lin2, Zetao Liao1, Dongfang Lin1, Chengcheng Hou1 and Jieruo Gu3, 1Rheumatology, The Affiliated Third Hospital of Sun Yat-san University, Rheumatology, Guangzhou, China, 2Rheumatology, third affiliated hospital of Sun Yat-sen Universtiy, Guangzhou, China, 3Medicine, Third Affiliated Hospital of Sun Yat-sen University, GuangZhou, China

    Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by chronic stimulation of the innate immune system by endogenous nucleic acids through toll-like receptors (TLRs) pathway, which…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology